Q-omics provides the consensus-scored ERICH1 profile across patient tissues and cancer cell-line models. ERICH1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ERICH1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ERICH1 RNA expression shows 19,884 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, HNSC, and ACC as cancer lineages where ERICH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERICH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERICH1 survival associations across molecular data types. ERICH1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERICH1 RNA expression–survival associations across cancer types. High ERICH1 expression shows unfavorable associations in KICH, LGG, MESO and ACC, but favorable associations in SKCM and READ. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ERICH1 RNA expression.
This table summarizes ERICH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ERICH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERICH1 shows lower tumor expression in THCA and BRCA and higher tumor expression in HNSC, COAD, STAD and KIRP. The HNSC box plot shows higher ERICH1 RNA expression in tumor versus normal tissue (log2 FC = +0.562, t-test p < 0.001).
This table shows molecular features associated with ERICH1 in patient tissues and cancer cell lines. In patient samples, ERICH1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ERICH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
